Lindbrook Capital’s Atara Biotherapeutics ATRA Stock Holding History

Lindbrook Capital’s Portfolio ATRA Stock Details ATRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-5	Closed	-$345	–	2717
2023 Q1	$345	Hold	5	–	–	﹤0.01%	2665
2022 Q4	$390	Sell	5 -15	-75%	-$1.56K	﹤0.01%	2634
2022 Q3	$2K	Buy	20 +10	+100%	+$1.12K	﹤0.01%	1985
2022 Q2	$2K	Buy	+10	New	+$1.63K	﹤0.01%	1904
2021 Q2	–	Sell	-2	Closed	-$1K	–	1910
2021 Q1	$1K	Hold	2	–	–	﹤0.01%	1667
2020 Q4	$1K	Hold	2	–	–	﹤0.01%	1569
2020 Q3	$1K	Sell	2 -12	-86%	-$4.09K	﹤0.01%	1507
2020 Q2	$5K	Buy	+14	New	+$3.54K	﹤0.01%	1066

Other funds holding ATRA

Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Lindbrook Capital's ATRA Position: Q2 2023 in Review

Lindbrook Capital sold out of Atara Biotherapeutics (ATRA) in Q2 2023, closing a stake of 5 shares — an estimated $345 sold.

Lindbrook Capital first reported a position in ATRA in Q2 2020 and held it in 8 quarters. The position peaked at $5K in Q2 2020. 118 funds tracked by Wall St. Rank hold ATRA as of Q2 2023.

Lindbrook Capital reported no remaining Atara Biotherapeutics position as of Q2 2023 after selling out during the quarter.
Lindbrook Capital sold 5 Atara Biotherapeutics shares in Q2 2023, an estimated $345.
Lindbrook Capital first reported a position in Atara Biotherapeutics in Q2 2020 and held it in 8 quarters.
Lindbrook Capital's Atara Biotherapeutics position peaked at $5K in Q2 2020.
118 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q2 2023.

Based on Lindbrook Capital's 13F filing for Q2 2023, filed 31 Jul 2023.